Build Your Comparison

Side-by-side financial analysis
CTEV logo
CTEV
UNH logo
UNH
CVS logo
CVS
CI logo
CI
Try popular comparisons:

Stock Comparison

CTEV vs UNH vs CVS vs CI

Revenue, margins, valuation, and 5-year total return — side by side.

Live fundamentals10-year financials5-year price chart
CTEV
Claritev Corporation

Medical - Healthcare Information Services

HealthcareNYSE • US
Market Cap$502M
5Y Perf.+40.2%
UNH
UnitedHealth Group Incorporated

Medical - Healthcare Plans

HealthcareNYSE • US
Market Cap$363.94B
5Y Perf.-15.6%
CVS
CVS Health Corporation

Medical - Healthcare Plans

HealthcareNYSE • US
Market Cap$125.45B
5Y Perf.+49.6%
CI
Cigna Corporation

Medical - Healthcare Plans

HealthcareNYSE • US
Market Cap$73.63B
5Y Perf.-9.6%

CTEV vs UNH vs CVS vs CI — Key Financials

Market cap, revenue, margins, and valuation side-by-side.

Company Snapshot
CTEV logoCTEV
UNH logoUNH
CVS logoCVS
CI logoCI
IndustryMedical - Healthcare Information ServicesMedical - Healthcare PlansMedical - Healthcare PlansMedical - Healthcare Plans
Market Cap$502M$363.94B$125.45B$73.63B
Revenue (TTM)$979M$449.71B$407.90B$277.94B
Net Income (TTM)$-287M$12.04B$2.93B$6.29B
Gross Margin61.1%18.8%13.9%9.3%
Operating Margin4.3%4.2%1.5%3.4%
Forward P/E21.8x13.3x9.2x
Total Debt$4.63B$78.39B$93.59B$31.46B
Cash & Equiv.$17M$24.36B$8.51B$7.68B

CTEV vs UNH vs CVS vs CILong-Term Stock Performance

Price return indexed to 100 at period start. Dividends excluded.

CTEV
UNH
CVS
CI
StockFeb 25Jun 26Return
Claritev Corporation (CTEV)100140.2+40.2%
UnitedHealth Group … (UNH)10084.4-15.6%
CVS Health Corporat… (CVS)100149.6+49.6%
Cigna Corporation (CI)10090.4-9.6%

Price return only. Dividends and distributions are not included.

Quick Verdict: CTEV vs UNH vs CVS vs CI

Each card shows where this stock fits in a portfolio — not just who wins on paper.

Bottom line: CVS leads in 3 of 7 categories, making it the strongest pick for capital preservation and lower volatility and dividend income and shareholder returns. UnitedHealth Group Incorporated is the stronger pick specifically for growth and revenue expansion and profitability and margin quality. CI also leads in specific categories worth noting. As sector peers, any of these can serve as alternatives in the same allocation.
🥇CVS emerged as the overall leader. Track its performance:
CTEV
Claritev Corporation
The Secondary Option

CTEV lags the leaders in this set but could rank higher in a more targeted comparison.

Best for: healthcare exposure
UNH
UnitedHealth Group Incorporated
The Insurance Pick

UNH is the #2 pick in this set and the best alternative if growth exposure and long-term compounding is your priority.

  • Rev growth 11.8%, EPS growth -14.7%, 3Y rev CAGR 11.4%
  • 230.8% 10Y total return vs CI's 140.6%
  • 11.8% revenue growth vs CTEV's 3.7%
  • 2.7% margin vs CTEV's -29.3%
Best for: growth exposure and long-term compounding
CVS
CVS Health Corporation
The Insurance Pick

CVS carries the broadest edge in this set and is the clearest fit for income & stability and defensive.

  • Dividend streak 0 yrs, beta 0.19, yield 2.7%
  • Beta 0.19, yield 2.7%, current ratio 0.84x
  • Beta 0.19 vs CTEV's 2.26
  • 2.7% yield, vs UNH's 2.2%, (1 stock pays no dividend)
Best for: income & stability and defensive
CI
Cigna Corporation
The Insurance Pick

CI is the clearest fit if your priority is sleep-well-at-night.

  • Lower volatility, beta 0.40, Low D/E 75.1%, current ratio 0.85x
  • Lower P/E (9.2x vs 21.8x)
  • 4.1% ROA vs CTEV's -5.8%, ROIC 10.4% vs 0.7%
Best for: sleep-well-at-night
See the full category breakdown
CategoryWinnerWhy
GrowthUNH logoUNH11.8% revenue growth vs CTEV's 3.7%
ValueCI logoCILower P/E (9.2x vs 21.8x)
Quality / MarginsUNH logoUNH2.7% margin vs CTEV's -29.3%
Stability / SafetyCVS logoCVSBeta 0.19 vs CTEV's 2.26
DividendsCVS logoCVS2.7% yield, vs UNH's 2.2%, (1 stock pays no dividend)
Momentum (1Y)CVS logoCVS+51.1% vs CTEV's -27.1%
Efficiency (ROA)CI logoCI4.1% ROA vs CTEV's -5.8%, ROIC 10.4% vs 0.7%

CTEV vs UNH vs CVS vs CI — Revenue Breakdown by Segment

How each company's revenue is distributed across its business units

Discover the Biotech & Healthcare Stocks Theme

These companies are key players in the Biotech & Healthcare Stocks ecosystem. See how they stack up against the rest of the sector.

Explore Theme
CTEVClaritev Corporation
FY 2025
Network Solutions
100.0%$207M
UNHUnitedHealth Group Incorporated
FY 2025
Unitedhealthcare
94.4%$332.4B
Optumhealth
5.6%$19.8B
CVSCVS Health Corporation
FY 2025
Pharmacy Revenue
58.9%$229.0B
Premiums
34.6%$134.8B
Front Store Revenue
5.5%$21.5B
Product and Service, Other
1.0%$3.9B
CICigna Corporation
FY 2025
Evernorth
83.2%$235.0B
Cigna Healthcare
16.8%$47.4B

CTEV vs UNH vs CVS vs CI — Financial Metrics

Side-by-side numbers across 4 stocks — who leads on profitability, valuation, growth, and risk.

BEST OVERALLCILAGGINGUNH

Income & Cash Flow (Last 12 Months)

Evenly matched — CTEV and UNH and CVS each lead in 2 of 6 comparable metrics.

UNH is the larger business by revenue, generating $449.7B annually — 459.5x CTEV's $979M. UNH is the more profitable business, keeping 2.7% of every revenue dollar as net income compared to CTEV's -29.3%. On growth, CVS holds the edge at +6.2% YoY revenue growth, suggesting stronger near-term business momentum.

MetricCTEV logoCTEVClaritev Corporat…UNH logoUNHUnitedHealth Grou…CVS logoCVSCVS Health Corpor…CI logoCICigna Corporation
RevenueTrailing 12 months$979M$449.7B$407.9B$277.9B
EBITDAEarnings before interest/tax$490M$23.2B$10.5B$12.1B
Net IncomeAfter-tax profit-$287M$12.0B$2.9B$6.3B
Free Cash FlowCash after capex-$39M$19.7B$7.4B$7.7B
Gross MarginGross profit ÷ Revenue+61.1%+18.8%+13.9%+9.3%
Operating MarginEBIT ÷ Revenue+4.3%+4.2%+1.5%+3.4%
Net MarginNet income ÷ Revenue-29.3%+2.7%+0.7%+2.3%
FCF MarginFCF ÷ Revenue-4.0%+4.4%+1.8%+2.8%
Rev. Growth (YoY)Latest quarter vs prior year+5.8%+2.0%+6.2%+4.6%
EPS Growth (YoY)Latest quarter vs prior year-0.7%+0.7%+63.1%+29.1%
Evenly matched — CTEV and UNH and CVS each lead in 2 of 6 comparable metrics.

Valuation Metrics

CI leads this category, winning 4 of 6 comparable metrics.

At 12.6x trailing earnings, CI trades at a 82% valuation discount to CVS's 70.7x P/E. On an enterprise value basis, CI's 8.3x EV/EBITDA is more attractive than UNH's 17.9x.

MetricCTEV logoCTEVClaritev Corporat…UNH logoUNHUnitedHealth Grou…CVS logoCVSCVS Health Corpor…CI logoCICigna Corporation
Market CapShares × price$502M$363.9B$125.4B$73.6B
Enterprise ValueMkt cap + debt − cash$5.1B$418.0B$210.5B$97.4B
Trailing P/EPrice ÷ TTM EPS-1.70x30.31x70.73x12.60x
Forward P/EPrice ÷ next-FY EPS est.21.80x13.25x9.17x
PEG RatioP/E ÷ EPS growth rate
EV / EBITDAEnterprise value multiple10.37x17.92x14.04x8.28x
Price / SalesMarket cap ÷ Revenue0.52x0.81x0.31x0.27x
Price / BookPrice ÷ Book value/share3.59x1.66x1.77x
Price / FCFMarket cap ÷ FCF22.64x16.07x8.78x
CI leads this category, winning 4 of 6 comparable metrics.

Profitability & Efficiency

CI leads this category, winning 6 of 9 comparable metrics.

CI delivers a 15.1% return on equity — every $100 of shareholder capital generates $15 in annual profit, vs $4 for CVS. CI carries lower financial leverage with a 0.75x debt-to-equity ratio, signaling a more conservative balance sheet compared to CVS's 1.24x. On the Piotroski fundamental quality scale (0–9), CI scores 8/9 vs CVS's 5/9, reflecting strong financial health.

MetricCTEV logoCTEVClaritev Corporat…UNH logoUNHUnitedHealth Grou…CVS logoCVSCVS Health Corpor…CI logoCICigna Corporation
ROE (TTM)Return on equity+11.5%+3.9%+15.1%
ROA (TTM)Return on assets-5.8%+3.9%+1.1%+4.1%
ROICReturn on invested capital+0.7%+9.2%+5.0%+10.4%
ROCEReturn on capital employed+0.9%+9.7%+6.1%+9.2%
Piotroski ScoreFundamental quality 0–95658
Debt / EquityFinancial leverage0.77x1.24x0.75x
Net DebtTotal debt minus cash$4.6B$54.0B$85.1B$23.8B
Cash & Equiv.Liquid assets$17M$24.4B$8.5B$7.7B
Total DebtShort + long-term debt$4.6B$78.4B$93.6B$31.5B
Interest CoverageEBIT ÷ Interest expense0.18x4.71x2.11x6.77x
CI leads this category, winning 6 of 9 comparable metrics.

Total Returns (Dividends Reinvested)

CVS leads this category, winning 5 of 6 comparable metrics.

A $10,000 investment in CVS five years ago would be worth $13,421 today (with dividends reinvested), compared to $10,075 for CTEV. Over the past 12 months, CVS leads with a +51.1% total return vs CTEV's -27.1%. The 3-year compound annual growth rate (CAGR) favors CVS at 15.6% vs UNH's -3.2% — a key indicator of consistent wealth creation.

MetricCTEV logoCTEVClaritev Corporat…UNH logoUNHUnitedHealth Grou…CVS logoCVSCVS Health Corpor…CI logoCICigna Corporation
YTD ReturnYear-to-date-13.2%+20.5%+24.4%+1.2%
1-Year ReturnPast 12 months-27.1%+33.4%+51.1%-9.2%
3-Year ReturnCumulative with dividends+0.8%-9.2%+54.6%+9.8%
5-Year ReturnCumulative with dividends+0.8%+13.1%+34.2%+31.7%
10-Year ReturnCumulative with dividends+0.8%+230.8%+29.2%+140.6%
CAGR (3Y)Annualised 3-year return+0.3%-3.2%+15.6%+3.2%
CVS leads this category, winning 5 of 6 comparable metrics.

Risk & Volatility

Evenly matched — UNH and CVS each lead in 1 of 2 comparable metrics.

CVS is the less volatile stock with a 0.19 beta — it tends to amplify market swings less than CTEV's 2.26 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. UNH currently trades 96.4% from its 52-week high vs CTEV's 39.7% drawdown — a narrower gap to the peak suggests stronger recent price momentum.

MetricCTEV logoCTEVClaritev Corporat…UNH logoUNHUnitedHealth Grou…CVS logoCVSCVS Health Corpor…CI logoCICigna Corporation
Beta (5Y)Sensitivity to S&P 5002.26x0.63x0.19x0.40x
52-Week HighHighest price in past year$74.07$415.96$102.77$338.89
52-Week LowLowest price in past year$11.50$234.60$58.50$239.51
% of 52W HighCurrent price vs 52-week peak+39.7%+96.4%+95.7%+82.4%
RSI (14)Momentum oscillator 0–10058.657.764.048.4
Avg Volume (50D)Average daily shares traded139K6.9M7.6M1.4M
Evenly matched — UNH and CVS each lead in 1 of 2 comparable metrics.

Analyst Outlook

Evenly matched — UNH and CVS each lead in 1 of 2 comparable metrics.

Analyst consensus: CTEV as "Buy", UNH as "Buy", CVS as "Buy", CI as "Buy". Consensus price targets imply 33.4% upside for CTEV (target: $39) vs 5.4% for CVS (target: $104). For income investors, CVS offers the higher dividend yield at 2.72% vs CI's 2.17%.

MetricCTEV logoCTEVClaritev Corporat…UNH logoUNHUnitedHealth Grou…CVS logoCVSCVS Health Corpor…CI logoCICigna Corporation
Analyst RatingConsensus buy/hold/sellBuyBuyBuyBuy
Price TargetConsensus 12-month target$39.25$425.81$103.64$340.91
# AnalystsCovering analysts4524139
Dividend YieldAnnual dividend ÷ price+2.2%+2.7%+2.2%
Dividend StreakConsecutive years of raises1605
Dividend / ShareAnnual DPS$8.70$2.67$6.06
Buyback YieldShare repurchases ÷ mkt cap0.0%+1.5%0.0%+4.9%
Evenly matched — UNH and CVS each lead in 1 of 2 comparable metrics.
Key Takeaway

CI leads in 2 of 6 categories (Valuation Metrics, Profitability & Efficiency). CVS leads in 1 (Total Returns). 3 tied.

Best OverallCigna Corporation (CI)Leads 2 of 6 categories
Loading custom metrics...

CTEV vs UNH vs CVS vs CI: Key Questions Answered

10 questions · data-driven answers · updated daily

01

Is CTEV or UNH or CVS or CI a better buy right now?

For growth investors, UnitedHealth Group Incorporated (UNH) is the stronger pick with 11.

8% revenue growth year-over-year, versus 3. 7% for Claritev Corporation (CTEV). Cigna Corporation (CI) offers the better valuation at 12. 6x trailing P/E (9. 2x forward), making it the more compelling value choice. Analysts rate Claritev Corporation (CTEV) a "Buy" — based on 4 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

02

Which has the better valuation — CTEV or UNH or CVS or CI?

On trailing P/E, Cigna Corporation (CI) is the cheapest at 12.

6x versus CVS Health Corporation at 70. 7x. On forward P/E, Cigna Corporation is actually cheaper at 9. 2x.

03

Which is the better long-term investment — CTEV or UNH or CVS or CI?

Over the past 5 years, CVS Health Corporation (CVS) delivered a total return of +34.

2%, compared to +0. 8% for Claritev Corporation (CTEV). Over 10 years, the gap is even starker: UNH returned +230. 8% versus CTEV's +0. 8%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

04

Which is safer — CTEV or UNH or CVS or CI?

By beta (market sensitivity over 5 years), CVS Health Corporation (CVS) is the lower-risk stock at 0.

19β versus Claritev Corporation's 2. 26β — meaning CTEV is approximately 1111% more volatile than CVS relative to the S&P 500. On balance sheet safety, Cigna Corporation (CI) carries a lower debt/equity ratio of 75% versus 124% for CVS Health Corporation — giving it more financial flexibility in a downturn.

05

Which is growing faster — CTEV or UNH or CVS or CI?

By revenue growth (latest reported year), UnitedHealth Group Incorporated (UNH) is pulling ahead at 11.

8% versus 3. 7% for Claritev Corporation (CTEV). On earnings-per-share growth, the picture is similar: Claritev Corporation grew EPS 83. 0% year-over-year, compared to -62. 0% for CVS Health Corporation. Over a 3-year CAGR, CI leads at 15. 1% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

06

Which has better profit margins — CTEV or UNH or CVS or CI?

UnitedHealth Group Incorporated (UNH) is the more profitable company, earning 2.

7% net margin versus -29. 4% for Claritev Corporation — meaning it keeps 2. 7% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: CTEV leads at 4. 7% versus 2. 6% for CVS. At the gross margin level — before operating expenses — CTEV leads at 27. 6%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

07

Is CTEV or UNH or CVS or CI more undervalued right now?

On forward earnings alone, Cigna Corporation (CI) trades at 9.

2x forward P/E versus 21. 8x for UnitedHealth Group Incorporated — 12. 6x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for CTEV: 33. 4% to $39. 25.

08

Which pays a better dividend — CTEV or UNH or CVS or CI?

In this comparison, CVS (2.

7% yield), UNH (2. 2% yield), CI (2. 2% yield) pay a dividend. CTEV does not pay a meaningful dividend and should not be held primarily for income.

09

Is CTEV or UNH or CVS or CI better for a retirement portfolio?

For long-horizon retirement investors, CVS Health Corporation (CVS) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.

19), 2. 7% yield). Claritev Corporation (CTEV) carries a higher beta of 2. 26 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (CVS: +29. 2%, CTEV: +0. 8%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

10

What are the main differences between CTEV and UNH and CVS and CI?

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: CTEV is a small-cap quality compounder stock; UNH is a large-cap quality compounder stock; CVS is a mid-cap quality compounder stock; CI is a mid-cap deep-value stock. UNH, CVS, CI pay a dividend while CTEV does not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.

You Might Also Compare

Based on how these companies actually compete and overlap — not just which sector they're filed under.